Immune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review

Mogamulizumab is a monoclonal antibody targeting CC-chemokine receptor-4 that is approved as a second-line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion-related reactions and mogamulizumab-associated rash. Conversely, solid organ involvement in immune-related adverse events has been limited to sporadic reports. Regarding mogamulizumab, hepatobiliary complications appear to occur predominantly alongside the reactivation of viral hepatitis. As management differs substantially from that of infectious hepatitis and immune-mediated adverse events involving solid organs are potentially life-threatening, their early recognition and attribution to mogamulizumab therapy are of high clinical importance. Treatment depends on severity, and interruption of therapy may be required. We report five cases of non-infectious hepatobiliary adverse events during mogamulizumab treatment and summarize the current state of the literature. The aim is to emphasize the importance of early recognition of immune-mediated toxicities affecting solid organs during mogamulizumab therapy in the management of patients with cutaneous lymphomas.

Authors

Institutions

Publication Details

Journal
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Published
2026-11-17
DOI
https://doi.org/10.1111/ddg.70572x
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review

Uwe Hillen, Inga Hansen, Lisa Eisert, Miriam Mengoni et al.
3 links
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Cutaneous lymphoproliferative disorders research
article

Immune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review

Uwe Hillen, Inga Hansen, Lisa Eisert, Miriam Mengoni, Marion Wobser, Nina Booken, Stefan W. Schneider
article en

Abstract

Mogamulizumab is a monoclonal antibody targeting CC-chemokine receptor-4 that is approved as a second-line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion-related reactions and mogamulizumab-associated rash. Conversely, solid organ involvement in immune-related adverse events has been limited to sporadic reports. Regarding mogamulizumab, hepatobiliary complications appear to occur predominantly alongside the reactivation of viral hepatitis. As management differs substantially from that of infectious hepatitis and immune-mediated adverse events involving solid organs are potentially life-threatening, their early recognition and attribution to mogamulizumab therapy are of high clinical importance. Treatment depends on severity, and interruption of therapy may be required. We report five cases of non-infectious hepatobiliary adverse events during mogamulizumab treatment and summarize the current state of the literature. The aim is to emphasize the importance of early recognition of immune-mediated toxicities affecting solid organs during mogamulizumab therapy in the management of patients with cutaneous lymphomas.

JDDG Journal der Deutschen Dermatologischen Gesellschaft
University Medical Center Hamburg-Eppendorf (DE), Vivantes Klinikum (DE), University Hospital Schleswig-Holstein (DE), Universitätsklinikum Würzburg (DE), University Hospital Magdeburg (DE), University of Duisburg-Essen (DE), University of Lübeck (DE)
Good health and well-being
Cutaneous lymphoproliferative disorders research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon